ANDA 76138, held by Nostrum Laboratories. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 76138 (Ciprofloxacin Hydrochloride), held by Nostrum Laboratories, was first approved by FDA on Jun 9, 2004, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2004 | Original application | Approved |
| Ciprofloxacin HydrochlorideEQ 250MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Discontinued |
| Ciprofloxacin HydrochlorideEQ 500MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Discontinued |
| Ciprofloxacin HydrochlorideEQ 750MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Discontinued |
| Oct 5, 2006 | Supplement 7Labeling | Approved | None posted |
| May 11, 2005 | Supplement 2Labeling | Approved | None posted |
| Jun 9, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters